Clinical case of successful treatment of a patient with anaplastic thyroid cancer in combination with ischemic heart disease and critical multivessel coronary artery disease

B. G. Pkheshkhova; Пхешхова Б. Г.; A. M. Mudunov; Мудунов А. М.; M. B. Pak; Пак М. Б.; P. A. Zeynalova; Зейналова П. А.; A. A. Akhobekov; Ахобеков А. А.; M. M. Dombrovsky; Домбровский М. М.; Z. M. Cheishvili; Чеишвили З. М.; T. I. Kopaliani; Копалиани Т. И.

doi:10.17650/2782-3202-2023-3-3-42-47

Clinical case of successful treatment of a patient with anaplastic thyroid cancer in combination with ischemic heart disease and critical multivessel coronary artery disease

Authors: Pkheshkhova B.G.¹^,2, Mudunov A.M.¹^,3, Pak M.B.¹^,3, Zeynalova P.A.¹^,3, Akhobekov A.A.¹, Dombrovsky M.M.¹, Cheishvili Z.M.¹^,4, Kopaliani T.I.¹
Affiliations:
1. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
2. RUDN University
3. I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
4. A.N. Bakulev Center for Cardiovascular Surgery, Ministry of Health of Russia
Issue: Vol 3, No 3 (2023)
Pages: 42-47
Section: RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSIS AND SELECTION OF TREATMENT TACTICS
Published: 20.09.2023
URL: https://mdonco.abvpress.ru/jour/article/view/76
DOI: https://doi.org/10.17650/2782-3202-2023-3-3-42-47
ID: 76

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The article presents a clinical case of a patient with locally advanced anaplastic thyroid cancer and concomitant cardiovascular pathology. Anaplastic thyroid cancer is a very rare and highly aggressive disease requiring long-term multistage treatment, often using cardiotoxic drugs. Combination of this pathology with ischemic heart disease affecting coronary arteries is a complex clinical problem requiring timely evaluation of cardiac risk at every stage. Treatment of this patient cohort is possible only by a multidisciplinary team of specialists.

Keywords

anaplastic cancer, thyroid cancer, PD-L1, molecular diagnosis of thyroid cancer, immunotherapy, multivessel coronary artery disease, myocardial infarction, coronary artery bypass grafting

About the authors

B. G. Pkheshkhova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; RUDN University

Author for correspondence.
Email: belapkheshkhova@mail.ru
ORCID iD: 0000-0003-1448-1733

Bela Gazrailovna Pkheshkhova

143081

111 1^st Uspenskoe Shosse

117198

6 Miklukho-Maklaya St.

Moscow region

Lapino

Moscow

Russian Federation

A. M. Mudunov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0002-0918-3857

143081

111 1^st Uspenskoe Shosse

119991

Bld. 2, 8 Trubetskaya St.

Moscow region

Lapino

Moscow

Russian Federation

M. B. Pak

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-4546-0011

143081

111 1^st Uspenskoe Shosse

119991

Bld. 2, 8 Trubetskaya St.

Moscow region

Lapino

Moscow

Russian Federation

P. A. Zeynalova

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

ORCID iD: 0000-0003-1564-424X

143081

111 1^st Uspenskoe Shosse

119991

Bld. 2, 8 Trubetskaya St.

Moscow region

Lapino

Moscow

Russian Federation

A. A. Akhobekov

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0002-6395-5790

143081

111 1^st Uspenskoe Shosse

Moscow region

Lapino

Russian Federation

M. M. Dombrovsky

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0003-1639-7332

143081

111 1^st Uspenskoe Shosse

Moscow region

Lapino

Russian Federation

Z. M. Cheishvili

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; A.N. Bakulev Center for Cardiovascular Surgery, Ministry of Health of Russia

ORCID iD: 0000-0001-7791-6875

143081

111 1^st Uspenskoe Shosse

121552

135 Rublevskoe Shosse

Moscow region

Lapino

Moscow

Russian Federation

T. I. Kopaliani

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0009-0009-8543-6017

143081

111 1^st Uspenskoe Shosse

Moscow region

Lapino

Russian Federation

References

The JAES/JSTS task force on the guidelines for thyroid tumors clinical practice guidelines on the management of thyroid tumors 2018. J JAES JSTS 2018;35:1–87.
Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. doi: 10.3322/caac.21492
Smallridge R.C., Copland J.A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 2010;22(6):486–97. doi: 10.1016/j.clon.2010.03.013
Are C., Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13(4):453–64. doi: 10.1245/ASO.2006.05.042
Pathology and genetics of endocrine organs. WHO Classification of Tumours, 3^rd edn., V. 8. Ed. by R.A. de Lellis, R.V. Lloyd, P.U. Heitz, C. Eng. IARC Press, Lyon, France, 2004.
Sherman S.I. Anaplastic carcinoma: clinical aspects. In: Thyroid cancer: a comprehensive guide to clinical management. Ed. by L. Wartofsky, D. Van Nostrand. 2nd edn. Totowa: Humana Press, 2006. Pp. 629–632.
Untch B.R., Olson J.A. Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am 2006;15(3):661–79. doi: 10.1016/j.soc.2006.05.006
Asa S.L., Bedard Y.C. Fine-needle aspiration cytology and histopathology. In: Thyroid cancer: diagnosis and treatment. Ed. by O.H. Clark, S. Noguchi. St. Louis: Quality Medical Publishing, 2000. Pp. 105–126.
McIver B., Hay I.D., Giuffrida D.F. et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130(6):1028–34. doi: 10.1067/msy.2001.118266
Lee D.Y., Won J.-K., Choi H.S. et al. Recurrence and survival after gross total removal of resectable undifferentiated or poorly differentiated thyroid carcinoma. Thyroid 2016;26(9):1259–68. doi: 10.1089/thy.2016.0147
Pozdeyev N., Gay L.M., Sokol E.S. et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin Cancer Res 2018;24(13):3059–68. doi: 10.1158/1078-0432.CCR-18-0373
Mohebati A., Dilorenzo M., Palmer F. et al. Anaplastic thyroid carcinoma: a 25-year single-institution experience. Ann Surg Oncol 2014;21(5):1665–70. doi: 10.1245/s10434-014-3545-5
Flaherty K.T., Infante J.R., Daud A. et al. Combined BRA F and MEK inhibition in melanoma with BRA F V600 mutations. N Engl J Med 2012;367(18):1694–703. doi: 10.1056/NEJMoa1210093
Subbiah V., Kreitman R.J., Wainberg Z.A. et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRA F V600-mutant anaplastic thyroid cancer. J Clin Oncol 2018;36(1):7–13. doi: 10.1200/JCO.2017.73.6785
Capdevila J., Wirth L.J., Ernst T. et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol 2020; 38(23):2620–7. doi: 10.1200/JCO.19.02727
Bastman J.J., Serracino H.S., Zhu Y. et al. Tumor-infiltrating T cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2016;101(7):2863–73. doi: 10.1210/jc.2015-4227
Quintana R.A., Monlezun D.J., Davogustto G. et al. Outcomes following percutaneous coronary intervention in patients with cancer. Int J Cardiol 2020;300:106–12. doi: 10.1016/j.ijcard.2019.09.016

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register